Jacobs Engineering Group Inc. (Pasadena, Calif.; www.jacobs.com) was awarded a contract to provide engineering, procurement and construction management (EPCM) services for Biogen’s new manufacturing facility in Luterbach, Switzerland.
Under the terms of the agreement, Jacobs is providing EPCM services for Biogen’s fourth manufacturing plant. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. The company currently manufactures therapies in Cambridge, Massachusetts; Research Triangle Park, North Carolina; and Hillerød, Denmark.
Plans for the new facility include state-of-the-art biotech manufacturing technology, which is expected to triple the company’s global capacity to produce large protein-based drugs known as biologics.
Work on the facility was expected to begin in late 2015 with the plant fully operational by 2021.